investor losses

$DRVN stock plunges 40% after revealing multi-year accounting errors and material control weaknesses despite prior management certifications. Securities class action lawsuit filed.

Soleno Therapeutics faces class action lawsuit alleging false safety disclosures about DCCR drug candidate for Prader-Willi syndrome.

ADMA Biologics faces securities investigation for alleged channel stuffing. Stock fell 16.6% after allegations; class action lawsuit being prepared.

POET Technologies stock plunged 49% after Marvell Technology canceled purchase orders alleging confidentiality breaches, triggering investor recovery investigation.

Compass Therapeutics faces securities investigation after lead drug tovecimig fails overall survival endpoint in COMPANION-002 trial, triggering significant stock losses.

Law firm Johnson Fistel investigates POET Technologies after Marvell Semiconductor canceled all orders from subsidiary Celestial AI due to confidentiality breaches, triggering material stock decline.

Immutep shares plummet 82.6% after independent committee halts Phase III trial for lead candidate eftilagimod alfa due to futility.

Law firm investigating Twenty One Capital ($XXI) for potential securities violations including false statements and material information disclosure failures.

Schall Law Firm investigates $APUS, $ETS, $DXST for alleged securities fraud involving false statements and material disclosure failures. Affected shareholders may participate in class action.

PennyMac Financial ($PFSI) stock collapsed 33.3% to $99.92 after weak Q4 results; securities investigation launched exploring class action lawsuit for alleged material misstatements.

FTC sues Zillow and Redfin for alleged rental advertising collusion; Zillow stock drops 4.6% as law firm launches shareholder investigation.

$SES plunged 36.8% March 5 after weak Q4 results and 2026 guidance. Class action investigation underway alleging misleading analyst information.

Rosen Law Firm urges Aquestive Therapeutics investors with $100K+ losses to secure counsel before May 4 deadline in ongoing securities class action alleging false statements and disclosure failures.

Rosen Law Firm urges Snowflake investors with losses exceeding $100K to seek counsel before April 27, 2026 class action deadline.

Rosen Law Firm seeks lead plaintiffs with $100K+ losses in $FBRT securities class action alleging false dividend sustainability claims. April 27, 2026 deadline applies.

Rosen Law Firm urges Driven Brands investors with losses exceeding $100K to join securities litigation over alleged false statements and control weaknesses before May 8, 2026 deadline.

Rosen Law Firm investigates Barclays over £600M exposure to failed UK mortgage lender, triggering 3.99% and 2.3% stock declines.

Securities lawsuit filed against Atara Biotherapeutics over alleged misstatements regarding tabelecleucel manufacturing and failed ALLELE study. Lead plaintiff deadline May 22, 2026.

Rosen Law Firm solicits ODDITY Tech investors with $100k+ losses for securities class action over alleged false statements about business impact from advertising algorithm changes.

Class action lawsuit filed against $PINS for allegedly false statements on advertising revenues and tariff impacts. Lead plaintiff deadline: May 29, 2026.